384 related articles for article (PubMed ID: 35305396)
41. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial.
Song JY; Choi WS; Heo JY; Kim EJ; Lee JS; Jung DS; Kim SW; Park KH; Eom JS; Jeong SJ; Lee J; Kwon KT; Choi HJ; Sohn JW; Kim YK; Yoo BW; Jang IJ; Capeding MZ; Roman F; Breuer T; Wysocki P; Carter L; Sahastrabuddhe S; Song M; D'Cor N; Kim H; Ryu JH; Lee SJ; Park YW; Cheong HJ;
EClinicalMedicine; 2023 Oct; 64():102140. PubMed ID: 37711219
[TBL] [Abstract][Full Text] [Related]
42. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala.
Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V
Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597
[TBL] [Abstract][Full Text] [Related]
43. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.
Priddey A; Chen-Xu MXH; Cooper DJ; MacMillan S; Meisl G; Xu CK; Hosmillo M; Goodfellow IG; Kollyfas R; Doffinger R; Bradley JR; Mohorianu II; Jones R; Knowles TPJ; Smith R; Kosmoliaptsis V
Front Immunol; 2023; 14():1296148. PubMed ID: 38259440
[TBL] [Abstract][Full Text] [Related]
44. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
Davis C; Logan N; Tyson G; Orton R; Harvey WT; Perkins JS; Mollett G; Blacow RM; ; Peacock TP; Barclay WS; Cherepanov P; Palmarini M; Murcia PR; Patel AH; Robertson DL; Haughney J; Thomson EC; Willett BJ;
PLoS Pathog; 2021 Dec; 17(12):e1010022. PubMed ID: 34855916
[TBL] [Abstract][Full Text] [Related]
45. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents.
Canaday DH; Oyebanji OA; White E; Keresztesy D; Payne M; Wilk D; Carias L; Aung H; St Denis K; Sheehan ML; Berry SD; Cameron CM; Cameron MJ; Wilson BM; Balazs AB; King CL; Gravenstein S
EBioMedicine; 2022 Jun; 80():104066. PubMed ID: 35605428
[TBL] [Abstract][Full Text] [Related]
46. Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India-An Ambi-Directional Cohort Study.
Thomas J; Rajmohan P; Jose P; Kannan R; Jose R; Uttumadathil Gopinathan U; Raphael L; Baiju NM; Krishna S; Attokaran T; Bency A T J; Venugopal A; Sheela S; Kallempadam A; Jose L; Innah SJ; Varghese PR; George A
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005865
[TBL] [Abstract][Full Text] [Related]
47. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.
Souza WM; Amorim MR; Sesti-Costa R; Coimbra LD; Brunetti NS; Toledo-Teixeira DA; de Souza GF; Muraro SP; Parise PL; Barbosa PP; Bispo-Dos-Santos K; Mofatto LS; Simeoni CL; Claro IM; Duarte ASS; Coletti TM; Zangirolami AB; Costa-Lima C; Gomes ABSP; Buscaratti LI; Sales FC; Costa VA; Franco LAM; Candido DS; Pybus OG; de Jesus JG; Silva CAM; Ramundo MS; Ferreira GM; Pinho MC; Souza LM; Rocha EC; Andrade PS; Crispim MAE; Maktura GC; Manuli ER; Santos MNN; Camilo CC; Angerami RN; Moretti ML; Spilki FR; Arns CW; Addas-Carvalho M; Benites BD; Vinolo MAR; Mori MAS; Gaburo N; Dye C; Marques-Souza H; Marques RE; Farias AS; Diamond MS; Faria NR; Sabino EC; Granja F; Proença-Módena JL
Lancet Microbe; 2021 Oct; 2(10):e527-e535. PubMed ID: 34258603
[TBL] [Abstract][Full Text] [Related]
48. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Li JX; Hou LH; Gou JB; Yin ZD; Wu SP; Wang FZ; Zhang Z; Peng ZH; Zhu T; Shen HB; Chen W; Zhu FC;
Lancet Infect Dis; 2023 Oct; 23(10):1143-1152. PubMed ID: 37352880
[TBL] [Abstract][Full Text] [Related]
49. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
[TBL] [Abstract][Full Text] [Related]
51. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
van Gils MJ; Lavell A; van der Straten K; Appelman B; Bontjer I; Poniman M; Burger JA; Oomen M; Bouhuijs JH; van Vught LA; Slim MA; Schinkel M; Wynberg E; van Willigen HDG; Grobben M; Tejjani K; van Rijswijk J; Snitselaar JL; Caniels TG; ; Vlaar APJ; Prins M; de Jong MD; de Bree GJ; Sikkens JJ; Bomers MK; Sanders RW
PLoS Med; 2022 May; 19(5):e1003991. PubMed ID: 35580156
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
[TBL] [Abstract][Full Text] [Related]
53. A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naïve individuals.
Gelanew T; Mulu A; Abebe M; Bates TA; Wassie L; Tefer M; Fentahun D; Alemu A; Tamiru F; Assefa G; Bayih AG; Taffesse FG; Mihret A; Abdissa A
Res Sq; 2022 Jan; ():. PubMed ID: 35043108
[TBL] [Abstract][Full Text] [Related]
54. Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.
Kong W; Zhong Q; Chen M; Yu P; Xu R; Zhang L; Lai C; Deng M; Zhou Q; Xiong S; Liang Y; Wan L; Lin M; Wang M; Mai W; Chen L; Lei Y; Qin N; Zhu J; Ruan J; Huang Q; Kang A; Wang J; Li W; Ji T
J Med Virol; 2023 Jan; 95(1):e28163. PubMed ID: 36127294
[TBL] [Abstract][Full Text] [Related]
55. Ability of SpikoGen®, an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants.
Honda-Okubo Y; Antipov A; Andre G; Barati S; Kafi H; Petrovsky N
Immunology; 2023 Oct; 170(2):193-201. PubMed ID: 37199229
[TBL] [Abstract][Full Text] [Related]
56. Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors.
Parameswaran A; Apsingi S; Eachempati KK; Dannana CS; Jagathkar G; Iyer M; Aribandi H
Infection; 2022 Aug; 50(4):889-895. PubMed ID: 35129788
[TBL] [Abstract][Full Text] [Related]
57. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
[TBL] [Abstract][Full Text] [Related]
58. Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial).
Muadchimkaew M; Siripongboonsitti T; Wongpatcharawarakul S; Boonsankaew C; Tawinprai K; Soonklang K; Mahanonda N
Int J Infect Dis; 2022 Nov; 124():190-198. PubMed ID: 36180032
[TBL] [Abstract][Full Text] [Related]
59. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
60. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
